Mathias Schmidt

Mathias Schmidt

Company: ArmaGen

Job title: CEO


Valanafusp-Alpha: The Development Path of a Brain Penetrating Molecular Enzyme Replacement Therapy for the Treatment of Neurological & Somatic Symptoms pf MPS I 11:00 am

• The trojan horse platform of antibody-enzyme fusion proteins to transport therapeutics across the blood-brain-barrier • Discovery, validation and preclinical development of Valanafusp alpha, aka AGT- 181 • Phase II clinical proof of concept of Valanafusp alpha and its effect on pediatric patients with severe untransplanted MPS I • Regulatory pathway and clinical endpoints discussed…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.